AU2004294282B2 - Pharmaceutical combinations - Google Patents

Pharmaceutical combinations Download PDF

Info

Publication number
AU2004294282B2
AU2004294282B2 AU2004294282A AU2004294282A AU2004294282B2 AU 2004294282 B2 AU2004294282 B2 AU 2004294282B2 AU 2004294282 A AU2004294282 A AU 2004294282A AU 2004294282 A AU2004294282 A AU 2004294282A AU 2004294282 B2 AU2004294282 B2 AU 2004294282B2
Authority
AU
Australia
Prior art keywords
rapamycin
subject
methotrexate
hydroxyethyl
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2004294282A
Other languages
English (en)
Other versions
AU2004294282A1 (en
Inventor
Axel Maibucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004294282A1 publication Critical patent/AU2004294282A1/en
Application granted granted Critical
Publication of AU2004294282B2 publication Critical patent/AU2004294282B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2004294282A 2003-12-01 2004-11-30 Pharmaceutical combinations Expired - Fee Related AU2004294282B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0327840.5 2003-12-01
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds
PCT/EP2004/013587 WO2005053661A2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
AU2004294282A1 AU2004294282A1 (en) 2005-06-16
AU2004294282B2 true AU2004294282B2 (en) 2009-05-07

Family

ID=29798110

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004294282A Expired - Fee Related AU2004294282B2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations

Country Status (11)

Country Link
US (1) US20070117833A1 (https=)
EP (1) EP1819361A2 (https=)
JP (1) JP2007512381A (https=)
KR (1) KR20060122877A (https=)
CN (1) CN1886157A (https=)
AU (1) AU2004294282B2 (https=)
BR (1) BRPI0417146A (https=)
CA (1) CA2546738A1 (https=)
GB (1) GB0327840D0 (https=)
RU (1) RU2006123312A (https=)
WO (1) WO2005053661A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
AU2007204410A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mTOR inhibitor and antipolate compound
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
LT1983984T (lt) * 2006-02-02 2018-06-11 Novartis Ag Tuberozinės sklerozės gydymas
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041807A1 (en) * 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
WO2003027671A2 (en) * 2001-09-25 2003-04-03 Eirx Therapeutics Limited Apoptosis
WO2003057218A1 (en) * 2002-01-10 2003-07-17 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
WO2003064383A2 (en) * 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
AU2003247483A1 (en) * 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
JP2006517969A (ja) * 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041807A1 (en) * 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
WO2003027671A2 (en) * 2001-09-25 2003-04-03 Eirx Therapeutics Limited Apoptosis
WO2003057218A1 (en) * 2002-01-10 2003-07-17 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
WO2003064383A2 (en) * 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Boerbooms AM et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum. 1995 Vol. 24(6) pp 411-21. *
Choi HK et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002 Vol. 359(9313) pp 1173-7. *
Forre O et al. New treatment possibilities in rheumatoid arthritis. Scand J Rheumatol. 2000 Vol. 29(2) pp73-84. *
van Ede et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998 Vol. 27(5) pp 277-92. *

Also Published As

Publication number Publication date
WO2005053661A2 (en) 2005-06-16
WO2005053661A3 (en) 2005-12-29
AU2004294282A1 (en) 2005-06-16
CN1886157A (zh) 2006-12-27
RU2006123312A (ru) 2008-01-20
KR20060122877A (ko) 2006-11-30
US20070117833A1 (en) 2007-05-24
JP2007512381A (ja) 2007-05-17
GB0327840D0 (en) 2003-12-31
BRPI0417146A (pt) 2007-03-06
EP1819361A2 (en) 2007-08-22
CA2546738A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
Banerjee et al. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects
Johnston et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
Bruyn et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
US8119649B2 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
JP5902141B2 (ja) 脂質キナーゼおよびｍＴＯＲのデュアル阻害剤としてのイミダゾキノリン
JP2020105181A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
Furst et al. Effect of aspirin and sulindac on methotrexate clearance
CN101842010A (zh) 使用抗精神病的组合治疗产品来治疗精神分裂症的方法和组合物
AU2004294282B2 (en) Pharmaceutical combinations
MX2008014365A (es) Metodos para tratar enfermedades autoinmunitarias utilizando una molecula de fusion del activador de transmembrana-inmunoglobulina.
US20240058352A1 (en) Combination therapies for the treatment of cancer
MX2008011490A (es) Composiciones y metodos para tratar artritis reumatoide.
CN109069467A (zh) 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
EP3068491B1 (en) 7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity
Percy et al. Geropharmacology for the rheumatologist
Sorbera et al. CP-690550
MXPA06006220A (en) Pharmaceutical combinations
EP0505640B2 (en) Improved therapeutic method
AU2024353689A1 (en) Therapeutic agent for rheumatoid arthritis
WO2025226830A1 (en) Shp2 and egfr inhibitors for the treatment of chordoma
Avdeeva et al. THU0110 The Effect of Subcutaneous (SC) Methotrexate (MTX) and Adalimumab (ADA) on Cytokine Profile in MTX-Naive Patients with Early Rheumatoid Arthritis (RA)
CN117083283A (zh) 用于癌症治疗的联合疗法
HK40031991B (zh) 治疗和预防移植物抗宿主病的方法
Larsen et al. THU0193 Determination of the potential for an in vitro protein binding interaction between the leflunomide (lef) metabolite, a77 1726 and the sulfasalazine (ssz) metabolite, sulfapyridine (sp)
Kavanaugh et al. Rheumatoid Arthritis: Pathogenesis, Clinical Features, and Treatment

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee